Search Results

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Welcome Remarks Date & Time Thursday, November 2nd / 1:30 PM Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Developing new tools to uncover GPCR signaling patterns with Remi Janicot About Remi Janicot I was born in Paris (France) and grew up in Europe until I was 18. After graduating high school, I moved to America to pursue my passion for basketball while continuing high level studies. I played collegiate basketball and earned my bachelor’s at Ursinus College, a small school around Philadelphia where I graduated from in 2018. After that, I worked at Johns Hopkins in Baltimore as a research assistant investigating mechanisms and treatments for pediatric epilepsy. With my background in neuroscience, the lab of Dr. Mikel Garcia-Marcos seemed like a good fit as GPCRs are integral to the functioning of the nervous system (and much more). My particular projects revolve around developing new tools to study GPCR activity in ways that were not previously possible. This research has led to a first-author Cell article on the development of a new biosensor platform called ONE-GO biosensors. Overall, the lab works on diverse models and diseases, and has developed a wide array of tools to dissect GPCR/G protein signaling which I would be happy to discuss. Remi Janicot on the web Chobanian & Avedisian School of Medicine Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Biochemical Mechanisms Underlying Location Bias in GPCR Signaling Date & Time Saturday, November 4th / 8:40 AM Abstract Coming Soon About Sudarshan Rajagopal "Dr. Sudarshan Rajagopal is a physician-scientist and is currently an Associate Professor of Medicine and Biochemistry at Duke University School of Medicine. He obtained his B.S. in Chemistry from The University of Chicago in 1998 and subsequently enrolled in the Medical Scientist Training Program at The University of Chicago. During his doctoral work in the lab of Prof. Keith Moffat, he studied the structural mechanisms of bacterial photoreceptors using time-resolved Laue crystallography. He was awarded his PhD in 2004 and his MD in 2006. He then joined the Internal Medicine Residency training program at Duke University Medical Center. During his Cardiology fellowship, he trained in the lab of Dr. Robert J. Lefkowitz, where his research focused on biased agonism, with the development of approaches to quantify ligand bias and the identification of ACKR3 as an endogenously beta-arrestin-biased receptor. After completing his training, he joined the faculty at Duke, with a focus on the mechanisms underlying biased agonism at GPCRs and its contribution inflammation and cardiovascular disease. His group and others have shown that many of these ligands act as biased agonists for the same receptor. His lab is also interested in identifying novel signal transduction mechanisms of GPCRs, such as the formation of complexes between G proteins and beta-arrestins. His clinical focus is on pulmonary arterial hypertension, a disease of the pulmonary arterioles that causes right heart failure, and he serves as co-director of the Duke Pulmonary Vascular Disease Center." Sudarshan Rajagopal on the web The Rajagopal Lab Google Scholar Pubmed LinkedIn Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Session VI AGPCRs shaping the nervous system ADGRCs in glutamatergic synapse formation, maintenance and degeneration Yimin Zou Antibody-drug conjugates targeting CD97 in glioblastoma Dimitris Placantonakis Adhesion G protein-coupled receptor latrophilin-3 (ADGRL3) modulation of dopaminergic neurotransmission Nicole Perry-Hauser ADGRCs in glutamatergic synapse formation, maintenance and degeneration Yimin Zou Abstract "ADGRCs (Celsr1-3) are components of the conserved planar cell polarity (PCP) pathway, which establishes and maintains cell and tissue polarity along the tissue plane in all tissues. Work from our lab showed that the PCP components, including ADGRC2 and ADGRC3, are localized in the developing and adult synapses and interact with synaptic scaffold proteins and glutamate receptors and are responsible for the formation and stability of the vast majority of glutamatergic synapses in the mammalian brain. Initial impairment of synaptic functions, which occurs early in Alzheimer’s disease, and subsequent massive loss of synapses are closely correlated with the decline of cognitive function. We showed that oligomeric Aβ binds to ADGRC3 on the same domain required for the interaction with Frizzled3, weakens their interaction and assists Vangl2 in disassembling synapses. Conditionally knocking out Ryk, required for Vangl2 function, protected synapses and preserved cognitive function in a mouse model for Alzheimer’s. Massive synapse loss in the prefrontal cortex is a hallmark of massive depressive disorder. Injection of low-dose ketamine, an antidepressant, can lead to acute (in several hours) and sustained (up to several weeks) antidepressive effects. Restoration of synaptic connections induced by low-dose ketamine has been found associated with the sustained antidepressive effects. We showed that ADGRC2 and ADGRC3 are required for the restoration of glutamatergic synapses in prefrontal cortical neurons of chronically stressed animals and their behavioral remission induced by low-dose ketamine. I will also present ongoing work on the signaling mechanisms of how ADGRCs regulate synapse formation, maintenance and plasticity." About Yimin Zou "I received Ph.D from University of California at Davis and San Diego in 1995 and then postdoctoral training from University of California, San Francisco in 2000. I was an assistant and then associate professor with tenure at the University of Chicago from 2000 to 2006 and moved to University of California San Diego as an Associate Professor in 2006. I became full professor in 2011 and Vice Chair of the Neurobiology Department at UC San Diego in 2012. I served as the Chair of the Neurobiology Department at UC San Diego from 2014 to 2017. My research focus is the mechanisms of neural circuit development, function and disease." Yimin Zou on the web UC San Diego Antibody-drug conjugates targeting CD97 in glioblastoma Dimitris Placantonakis Abstract "Glioblastoma (GBM) is the most common and aggressive primary brain malignancy. Several adhesion G protein-coupled receptors (aGPCRs) have recently been shown to play critical roles in GBM biology. We showed that CD97 (ADGRE5), in particular, drives tumor growth via effects on GBM stem cell self-renewal and metabolism, but also has a therapeutically favorable expression pattern: it is highly expressed in all GBM specimens, but is absent from healthy brain tissue. To exploit this expression profile, we have developed antibody-drug conjugates (ADCs) targeting CD97, by screening a synthetic human antibody library. We initially tested the ADC using in vitro WST-8 viability assays in human GBM cell lines and cell types that lack CD97. We observed significantly lower LD50 values in patient-derived and U87 GBM cell cultures vs. CD97-lacking cells. We also found significantly lower LD50 values when treating human GBM cells with the ADC (0.6788 nM), as compared to control ADC targeting RSV glycoprotein F (19.964 nM). In vivo intratumoral administration of the ADC in patient-derived GBM xenografts in the brain of immunodeficient mice resulted in significant reduction of tumor growth and prolongation of survival of host mice. Collectively, these data suggest that ADCs targeting CD97 impair tumor growth in preclinical GBM models and are promising candidates for future clinical trials." Authors & Affiliations "Groff, Karenna; Donaldson, Hayley; Anderson, Sebastian; Pitti, Kiran; Wang, Shuai; Park, Christopher; Hattori, Takamitsu; Koide, Shohei; Placantonakis, Dimitris New York University Grossman School of Medicine" About Dimitris Placantonakis "Dimitris Placantonakis is a neurosurgeon-scientist at NYU Grossman School of Medicine in New York. As a clinician, he specializes in surgical treatment of brain tumors. His laboratory studies oncogenesis in glioblastoma, the most common brain malignancy, and chromatin organization in human neural development. His group has been particularly interested in the role adhesion GPCRs play in glioblastoma biology and their therapeutic targeting." Dimitris Placantonakis on the web Placantonakis Lab Google Scholar LinkedIn Adhesion G protein-coupled receptor latrophilin-3 (ADGRL3) modulation of dopaminergic neurotransmission Nicole Perry-Hauser Abstract Only available for AGPCR 24 Attendees Authors & Affiliations "Nicole A. Perry-Hauser1,2, Arturo Torres Herraez1,2, Dan Lowes1,2, Ying Zhu1,2, Siham Boumhaouad1,3, Eugene V. Mosharov1,2,4, David Sulzer1,2,4, Christoph Kellendonk1,2, and Jonathan A. Javitch1,2 1Departments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University, New York, NY 10032; 2Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY 10032; 3 Physiology and Physiopathology, Faculty of Sciences, Mohammed V University, Rabat 1014, Morocco; 4Department of Neurology, Columbia University, New York, NY 10032" About Nicole Perry-Hauser "I am an associate research scientist endeavoring to build a productive, independent scientific research career in adhesion G protein-coupled receptor (aGPCR) biology. My long-term research interests involve resolving signaling pathways downstream of aGPCRs and establishing how/if these receptors’ adhesive properties influence signaling events, and in turn whether signaling impacts synapse formation and neuronal wiring. I initially became interested in GPCR signal transduction during my graduate training in the Department of Pharmacology at Vanderbilt University where I studied under the co-mentorship of Dr. Vsevolod V. Gurevich and Dr. Tina M. Iverson. I then pursued a postdoctoral research position under the mentorship of Dr. Jonathan A. Javitch in the Department of Psychiatry at Columbia University Irving Medical Center." Nicole Perry-Hauser on the web LinkedIn Research Gate Pubmed Dr. GPCR < Previous Session Next Session >

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. JoAnn Trejo About Dr. JoAnn Trejo Dr. JoAnn Trejo earned her Ph.D. at UC San Diego. She completed her postdoctoral fellowship at UC San Francisco under the guidance of Professor Shaun Coughlin where she worked on the newly discovered protease-activated GPCRs. Dr. Trejo joined the faculty in the Department of Pharmacology at the University of North Carolina in 2000 and then moved to UC San Diego School Medicine, Department of Pharmacology in 2008, where she quickly rose through the ranks to tenured professor in 2012. In 2014, she was appointed Vice-Chair of the Department of Pharmacology. The long-term goal of Dr. Trejo’s research program is to gain a thorough and mechanistic understanding of processes that control cell signaling by protease-activated receptors (PARs) and the impact on vascular inflammation and cancer progression. PARs are GPCRs that are activated through an atypical irreversible proteolytic mechanism. The precise control of PAR signaling is critical for proper temporal and spatial dynamics of signaling and appropriate cellular responses. Discovering new aspects of PAR signaling is important for increasing the fundamental knowledge of GPCR biology and for the identification of drug targets and future drug development. Dr. Trejo’s research has focused on PAR1, which has important functions in hemostasis, thrombosis, inflammation, and cancer and is an important drug target. She has made numerous important discoveries related to the mechanisms that control PAR1 signaling and closely related family members and published extensively on this topic. Dr. Trejo has been continuously funded by the NIH for >20 years and was a recipient of the prestigious American Heart Association Established Investigator Award. Her laboratory is the recognized expert on protease-activated receptors, particularly PAR1, and over the years she has discovered novel aspects of GPCR biology, acquired critical expertise, and rigorous approaches to examine PAR1 function using human cultured cells and mouse models. Dr. Trejo has presented her studies at 52 national/international meetings and 66 academic seminars across the U.S. Dr. JoAnn Trejo on the web UC San Diego Trejo Lab Wikipedia LinkedIn Google Scholar Orcid Twitter UC San Diego School of Medicine Researchgate Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Jean Martin Beaulieu About Dr. Jean Martin Beaulieu Dr. Beaulieu received a Ph.D. in Neurological Sciences from McGill University and completed his post-doctoral training at Duke University. Prior to his recruitment Dr. Beaulieu was an associate professor and Canada Research Chair (Tier2) in the Department of Psychiatry and Neuroscience at Laval University. Dr. Beaulieu’s research is aimed at understanding how cellular and molecular mechanisms regulated by psychoactive drugs intersect with genetic risk factors for mental illnesses such as schizophrenia, depression, and bipolar disorder. Dr. Beaulieu has pioneered work establishing a role for Beta-arrestin signaling in the brain in vivo and has established its importance in D2 dopamine receptors (D2R) functions. These receptors belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target for drug development. In particular, D2R is the main pharmacological target of antipsychotic drugs prescribed for schizophrenia and bipolar disorders. Work by the Beaulieu Lab has demonstrated that mood stabilizer drugs (e.g. lithium) used for bipolar disorder therapy target signaling mechanisms regulated by dopamine receptors, thus providing a framework to understand how different drug classes can engage overlapping cellular mechanisms to exert their action. The Beaulieu group is presently investigating how cell surface express proteins can act as allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins for the development of new pharmaceutical agents. Translational validation is important to validate findings obtained from experimental models research and bridge the gap between bench and bedside. Working in collaboration with geneticists, the Beaulieu-Lab has identified interactions between cellular mechanisms engaged by D2R and psychiatric drugs with genetic risk factors implicated in schizophrenia by large whole-genome association studies (GWAS) in humans. These investigations have led to the identification of an RNA binding protein (FXR1P) involved in the regulation of protein synthesis as a potential downstream effector of the action of mood stabilizers and other psychoactive drugs. In addition to basic research, the Beaulieu group is also actively implicated in translational research and industry collaboration to develop new drugs and drug development technology. Dr. Jean Martin Beaulieu on the web University of Toronto Google Scholar LinkedIn ResearchGate Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Catherine Demery shares how she found clarity and purpose in academic opioid research. From her early doubts to designing preclinical models of fentanyl and xylazine overdose, she reflects on staying in academia, building translational experiments, and using real-world data to drive impactful science in the GPCR research community. << Back to podcast list Dr. GPCR Podcast Strategic Partners Xylazine, Fentanyl, and the Fight for Breath with Catherine Demery Two drugs. Two different mechanisms. One deadly outcome. Fentanyl and xylazine are pushing the opioid crisis into dangerous new territory, and Catherine Demery is on the front lines of the science trying to stop it. In this gripping conversation, Catherine, a PhD candidate at the University of Michigan, shares how personal loss and an unconventional career path—industry chemist, NIH researcher, and now GPCR pharmacologist—led her to investigate how these drugs shut down breathing in different ways. Her research combines cutting-edge GPCR signaling studies with real-time public health data from Michigan’s Red Project, revealing how fentanyl slows inhalation, xylazine prolongs exhalation, and together they drop heart rate to dangerous lows. And while users aren’t asking for xylazine, dealers are lacing it into the supply—driving overdose deaths higher. Why This Matters Fentanyl : Potent synthetic opioid that decreases inhalation rate. Xylazine : Veterinary sedative that prolongs exhalation and induces bradycardia—acting through alpha-2 adrenergic, not opioid, receptors. The Combo : Not just additive—lethal. Street Data : Xylazine-laced fentanyl in Michigan has jumped 30–60% in recent years. What You’ll Learn in This Episode How industry lab experience builds the discipline needed for academic research. Why xylazine is an emerging overdose threat and how it differs mechanistically from opioids. The methods used to measure respiratory depression in live models. How loss and lived experience can sharpen scientific focus. The role of public health programs in informing lab research. How GPCR pharmacology connects molecular insights to real-world interventions. Who Should Listen This episode is especially relevant for: GPCR drug discovery scientists Respiratory pharmacologists Addiction researchers Public health professionals Early-career scientists navigating non-linear paths About Catherine Demery Catherine Demery didn’t set out to be on the front lines of the opioid crisis. After earning her undergraduate degree in biochemistry from the University of Michigan, she deferred pharmacy school, unsure if that path felt right. Instead, she went hands-on—working as an analytical chemist in a GLP/GMP-regulated CRO, where precision and discipline became second nature. That led her to a master’s in pharmacogenomics at Manchester University, igniting her fascination with how genetics and drugs interact. Her next stop: the NIH, studying the immunology of pregnancy. But loss has a way of sharpening focus—friends lost to overdose brought the opioid epidemic into painful clarity. Catherine decided to act where she could make the biggest difference: in the lab. Today, as a PhD candidate in the labs of Dr. John Traynor and Dr. Jessica Anand at the University of Michigan, Catherine investigates how fentanyl and xylazine shut down breathing through different mechanisms—work that blends receptor pharmacology, preclinical models, and public health data to tackle one of the most urgent challenges in addiction science. Catherine Demery on the web LinkedIn Google Scholar University of Michigan 🎧 Listen now and see how one scientist is turning molecules into a mission, bridging the gap between receptor pharmacology and the urgent fight to save lives in the opioid epidemic. __________ Keyword Cloud GPCR research community , Dr. GPCR ecosystem , GPCR training program , GPCR podcast , opioid pharmacology , xylazine research , mu opioid receptor , pharmacogenomics , fentanyl epidemic , preclinical pharmacology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Robert Laprairie About Dr. Robert Laprairie Dr. Robert Laprairie is an Associate Professor and the Saskatchewan Research Chair in Drug Discovery and Development in the College of Pharmacy and Nutrition at the University of Saskatchewan. The focus of his research is the molecular pharmacology of cannabinoids and cannabinoid receptors. He was the 2018 and 2021 recipient of the Young Investigator of the Year Awards from the British Pharmacological Society and International Cannabinoid Research Society (ICRS), respectively. In 2019 he became the Director of Education for the Canadian Consortium for the Investigation of Cannabinoids (CCIC) and now also serves as the organization’s President. Dr. Robert Laprairie on the web University of Saskatchewan Twitter Instagram ResearchGate Google Scholar Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule "Have a nice weekend, and I'll see you tomorrow!": RAMP-interacting GPCR Pathways Date & Time Thursday, November 2nd / 4:30 PM Keynote Talk Abstract Coming Soon About Kathleen Caron "Kathleen M. Caron, Ph.D. is the Frederik L. Eldridge Distinguished Professor and Chair of the Department of Cell Biology & Physiology at The University of North Carolina at Chapel Hill—a large, interdisciplinary basic science department consistently ranked in the Top 5 in the Nation in NIH funding. Dr. Caron received a BS in Biology and BA in Philosophy at Emory University and a PhD at Duke University while training with Dr. Keith Parker to elucidate the role of steroidogenesis in regulating sexual determination and adrenal and gonadal development using genetic mouse models. She pursued postdoctoral training with Nobel Laureate Dr. Oliver Smithies at UNC-CH, where she was the first to discover the essential role of adrenomedullin peptide for embryonic survival. With a special emphasis on G protein coupled receptors and receptor activity modifying proteins in vascular biology, the Caron laboratory has gained valuable insights into the genetic basis and pathophysiology of lymphatic vascular disease, preeclampsia and sex-dependent cardiovascular disease. Dr. Caron has received numerous awards including a Burroughs Wellcome Fund Career Award in the Biomedical Sciences, an Established Investigator Award and an Innovator Award from the American Heart Association, a Jefferson Pilot Award in Biomedical Sciences and a UNC-CH Mentoring Award. She currently serves as Associate Editor of Physiological Reviews; the #1 ranked journal in Physiology (IF 46.5). Dr. Caron is also past Associate Editor at JCI and served as the inaugural Associate Editor at ACS-Pharmacology and Translational Science. Dr. Caron currently holds multiple scientific advisory roles in academia, industry and the National Institutes of Health." Kathleen Caron on the web UNC-Chapel Hill Department of Cell Biology and Physiology UNC Lineberger Comprehensive Cancer Center Twitter Google Scholar ORCID ResearchGate Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Targeting adenosine signaling for immuno-oncology Date & Time Friday, November 3rd / 4:35 PM Abstract "Adenosine (ADO) signaling through A2A and A2B G protein-coupled receptors is increasingly recognized as an important immune checkpoint in the generation of anti-tumor immunity. Potent inhibitors of ADO signaling are currently being tested in cancer patients, including in randomized Phase 3 trial. I will present our recent work on adenosine-producing ectonucleotidases and adenosine signaling and discuss unexpected links between the adenosinergic pathway, DNA damage response and metabolic regulation." Authors and Affiliations John Stagg , David Allard . Centre de Recherche du Centre Hospitalier de l'Université de Montréal; Faculté de Pharmacie. 900 St-Denis, Montréal, QC, H2X 0A9. About John Stagg "John Stagg is a Professor of Pharmacy at Université de Montréal and researcher at the CHUM Research Centre. Distinguished immunologist, Dr Stagg is recognized for having identified the adenosine-producing enzyme CD73 as a new cancer target, and for his translational work in immuno-oncology. Dr Stagg has served as an expert consultant in the development of adenosine-targeting drugs, several of which now in clinical trials. Dr Stagg is a member of the Board of Directors of BioCanRx, Canada's Immunotherapy Network, co-founder and permanent member of the Scientific Advisory Board (SAB) of Surface Oncology, a clinical stage company developing next generation immunotherapies, and member of the SAB of Domain Therapeutics, a biopharmaceutical company focused on GPCR in immuno-oncology." John Stagg on the web University of Montréal Québec Cancer Consortium The University of Montreal Hospital Research Centre Pubmed LinkedIn Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Simone Prömel & Dr. Ines Liebscher About Dr. Simone Prömel Simone Prömel is currently a professor of cell biology at the Heinrich Heine University Düsseldorf, Germany. Being a biochemist by training, she completed her Ph.D. at the Institute of Biochemistry at the University of Oxford, UK. During this time, she discovered her love for Adhesion GPCRs and started delineating the molecular mechanisms of the Adhesion GPCR Latrophilin-1. These extraordinary receptors, about which there was not much known other than that they are huge and somehow play important roles in health and disease, fascinated her so much that she continued working on them when she started her own lab at Leipzig University. There she focused on the different modes of action of Adhesion GPCRs and found that they do not only mediate classical G protein signals into cells but can also communicate solely via their N termini. Today, she and her team are working on the questions of how Adhesion GPCRs integrate the different signals on a molecular level and how these are translated into physiological functions in various model organisms. Together with Ines Liebscher, Simone is leading an EU-funded COST Network on Adhesion GPCRs: CA18240 Adher´n Rise. Dr. Simone Prömel on the web Prömel Lab Pubmed Researchgate Twitter Dr. GPCR Ecosystem About Dr. Ines Liebscher Dr. Liebscher is a Professor at the Rudolf Schönheimer Institute of Biochemistry at the Medical Faculty of the Leipzig University. During her medical studies in Leipzig, she had her first encounter with an orphan GPCR as the subject of her MD thesis. Being faced with the vast unknown biochemical and pharmacological territory that would be helpful to study orphan receptors she enrolled in the MD/Ph.D. program of Leipzig University. Her postdoctoral work leads her to investigate a whole family of orphan receptors: adhesion GPCRs. With the little knowledge on these receptors available, there were multiple questions to tackle. Starting with proving and characterizing G-protein coupling, Ines spends several years studying the activation mechanism of adhesion GPCRs. In collaboration with great fellow adhesion GPCR scientists around the globe she established a tethered agonist -extracellular matrix- mechano-activation- activation scenario that forms the basis for her current projects that focus on the structural and physiological implications of these findings. Together with Simone Prömel, Ines is leading a COST Network on adhesion GPCRs: CA18240 Adher'nRise. Dr. Ines Liebscher on the web Website LinkedIn Researchgate Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Advanced data analysis for GPCR pharmacology Dr. Samuel Hoare Get Started Premium Members benefits: - Subscribe and save 25% on every GPCR Course - Early-bird access - Recordings will be available < Back to GPCR courses Watch recording Your Instructor Dr. Samuel Hoare

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Eleonora Comeo About this episode Eleonora Comeo is a doctoral candidate in Medicinal Chemistry and Drug Discovery in the joint program of the University of Nottingham in the UK and Monash University in Australia. We sat down to chat about GPCRs, synthesizing labeled ligands, and her unique position that allows her to work with GPCR scientists on 2 continents. We also touched on how COVID-19 affected her Ph.D. work. Eleonora Comeo on the web LinkedIn ResearchGate Pubmed Google Scholar Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Vulnerability in Ovarian Cancer Date & Time Friday, November 3rd / 3:55 PM Abstract Coming Soon About Robert Rottapel "Dr. Rottapel is a Senior Scientist at the Princess Margaret Cancer Centre where he holds the Amgen Chair for Cancer Research. He is a Professor in the Departments of Medicine, Immunology and Medical Biophysics at the University of Toronto. After completing his medical studies at George Washington University, the NIH and UCLA, he pursued his postdoctoral studies with Allan Bernstein at the Lunenfeld Research Institute in Toronto and with Patrice Dubreuil at INSERM, France. Dr. Rottapel is a clinical rheumatologist at St. Michael's Hospital, University of Toronto. His clinical expertise is in monogenic autoinflammatory disorders and the autoimmune adverse effect resulting from checkpoint inhibitors in cancer patients. Dr. Rottapel’s research interests lies in the elucidation of signal transduction pathways in cancer, immune and bone cells. He has focussed on developing a comprehensive map of ovarian cancer essential genes using whole genome RNAi and CRISPR technology. This approach has provided insight into novel drivers resulting from the widespread gene copy number aberrations observed in ovarian cancer and the identification of emergent vulnerabilities associated with adaptation pathways required to buffer cancer associated stress states. Several of these targets are being developed for potential new therapeutic strategies in ovarian and pancreatic cancer. A second area of interest has been the elucidation of the molecular basis for a rare autosomal human disease called Cherubism. The adapter protein 3BP2 is mutated in Cherubism. The Rottapel lab has shown that 3BP2 has pleiotrophic function controlling bone homeostasis, immune cell function and scavenger receptor activation." Robert Rottapel on the web The Rottapel Lab Ontario Institute for Cancer Research University of Toronto Pubmed Google Scholar LinkedIn Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Julia Gardner About Julia Gardner Julia is a senior undergraduate student at Duke University, where she studies chemistry and Chinese. Julia has been working as a researcher in Duke's Rajagopal Lab since her first year as an undergraduate. In the Rajagopal Lab, Julia studies the mechanisms of 'biased signaling' at GPCRs, with a specific focus on the chemokine receptor CXCR3. She recently led a project that demonstrated the GPCR kinases (GRKs) can translocate to endosomes, and that the subcellular localization of the GRKs affects a GPCR's biased signaling profile. Last summer, Julia worked at as the first-ever summer intern at Septerna, the GPCR-based biotechnology company founded by Duke Nobel laureate Dr. Robert Lefkowitz. In the fall, Julia will begin her MD/PhD training. Julia Gardner on the web Rajagopal Lab Google Scholar ResearchGate LinkedIn Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Coffee Break 5 Date & Time Saturday, November 4th / 9:55 AM Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Dopamine-Mediated Motor Recovery after Ischemic Stroke Date & Time Friday, November 3rd / 8:30 AM Abstract Coming Soon About Mario Tiberi "I did my graduate research on the regulation of axonal transport by tricyclic antidepressants (M.Sc.) and molecular pharmacology of opioid receptors (Ph.D.) in the Department of Pharmacology at the Université de Montréal under the mentorship of Dr. Pierre-André Lavoie and Dr. Jacques Magnan, respectively. I then pursued my postdoctoral training at Duke University in the laboratory of Dr. Marc Caron, where I cloned the dopamine D5 receptor gene and investigated the regulation of dopaminergic and adrenergic receptors. My addiction for dopamine led me to the Ottawa Hospital Research Institute (then the Moses and Rose Loeb Research Institute) to develop my independent research program. The Tiberi Lab pursues the study of the molecular, structural, pharmacological and signaling features of dopamine (DA) receptors. We are also currently developing the translational component of our research to capitalize on the druggability potential of GPCRs. More specifically, we investigate the druggability potential of new signaling partners we identified that drive the formation of different DA receptor complexes. We hope our research will aid in the development of new therapeutic interventions for the alleviation of L-DOPA-induced dyskinesia in Parkinson’s Disease and improvement of post-stroke recovery." Mario Tiberi on the web University of Ottawa Pubmed Google Scholar ResearchGate LinkedIn Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Brian Bender About Dr. Brian Bender Dr. Bender completed his undergraduate studies at Colgate University in upstate New York with a degree in Biochemistry. Between undergraduate and graduate school Brian worked as a technician in an academic lab before moving to Nashville, TN for graduate work at Vanderbilt University where he joined the Department of Pharmacology. Brain’s work there primarily focused on structure prediction of GPCRs from sparse experimental data. He then moved to the University of California in San Francisco to continue his training as a postdoctoral researcher where he used structural models of GPCRs to virtually screen large compound libraries with the goal of finding new chemical matter to probe understudied and orphan receptors. Brian is involved in organizing the GRC/GRS Molecular Pharmacology meeting, which has been postponed to 2023. Brian is one of the organizers of the upcoming Transatlantic ECI GPCR Symposium . Dr. Brian Bender on the web LinkedIn Twitter ResearchGate Dr.GPCR Member Google Scholar Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Complimentary Reception dinner MENU Four Mushroom Soup Tomato, Panela Cheese, and Spinach tower with Oregano Vinaigrette Cane Sugar and Arbol Chile Lacquered Duck Monte Cristo Chocolate Cake Coffee or Tea Vegetarian option* -Mushroom-stuffed chiles on refried bean sauce- instead of the duck < Previous Session Next Session >

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Session V Structural mechanisms of AGPCR signaling and function Structural Determinants Of GAIN Domain Autoproteolysis And Cleavage Resistance Of Adhesion G Protein-Coupled Receptors Fabian Pohl Structural studies of the CELSR1 extracellular region reveal a compact multidomain module of fourteen domains which regulates signaling Sumit Bandekar Unveiling the GPS Cleavage Mechanism in ADGRL1 with QM/MM Florian Seufert Structural Determinants Of GAIN Domain Autoproteolysis And Cleavage Resistance Of Adhesion G Protein-Coupled Receptors Fabian Pohl Abstract "The GPCR autoproteolysis-inducing (GAIN) domain is a hallmark feature of adhe-sion G-protein coupled receptors (ADGRs), as this extracellular domain contains an integral agonistic sequence (Stachel) for activation via binding to the 7-transmembrane (7TM) helical domain of the receptor. Many ADGRs are autoproteo-lytically cleaved at the GPCR proteolysis site (GPS), an HXS/T motif within the GAIN domain. However, several ADGRs can be activated without GPS cleavage. We de-termined the crystal structure of the human ADGRB2/BAI2 hormone receptor (HormR) and GAIN domains and found that this ADGR is resistant to autoproteolysis despite the presence of a canonical HLS sequence at the GPS. By structural com-parison and with the help of molecular dynamics (MD) simulations we identified several unique structural features that are important for autoproteolytic cleavage, beyond the canonical HXS/T motif. Disruption of these features reduced autoproteo-lytic activity in ADGRL1/LPHN1 and restored cleavage competence of AD-GRB3/BAI3. Furthermore, conservation analysis indicates that wild type ADGRB2 and ADGRB3 are GPS cleavage-incompetent receptors." Authors & Affiliations "Fabian Pohl1, Florian Seufert2, Yin Kwan Chung3, Daniela Volke1, Ralf Hoffmann1, Torsten Schöneberg4, Tobias Langenhan3, Peter W. Hildebrand2, Norbert Sträter1 1 Institute of Bioanalytical Chemistry, Leipzig University, Deutscher Platz 5, 04103 Leipzig, Germany 2 Institute of Medical Physics and Biophysics, Leipzig University, Härtelstr. 16-18, D-04107 Leipzig 3 Rudolf-Schönheimer-Institute of Biochemistry, Division of General Biochemistry, Leipzig University, Johannisallee 30, D-04103 Leipzig 4 Rudolf-Schönheimer-Institute of Biochemistry, Division of Molecular Biochemis-try, Leipzig University, Johannisallee 30, D-04103 Leipzig" About Fabian Pohl "Mar 2023 – Today Postdoc, University Leipzig, Group of Prof. Langenhan Apr 2016 – Nov 2022 PhD candidate, University Leipzig, Group of Prof. Sträter Oct 2011 – Mar 2016 Master of Science in chemistry, University Leipzig Oct 2008 – Sep 2011 Bachelor of Science in chemistry, University Leipzig" Fabian Pohl on the web Langenhan Lab Structural studies of the CELSR1 extracellular region reveal a compact multidomain module of fourteen domains which regulates signaling Sumit Bandekar Abstract "Cadherin EGF Laminin G seven-pass G-type receptors (CELSRs) are conserved adhesion G protein-coupled receptors; they are essential for embryogenesis and neural development. CELSRs have large and enigmatic extracellular regions (ECRs) with nine cadherin repeats and a variety of adhesion domains which couple cell adhesion to signaling. CELSRs regulate planar cell polarity, including the closure of the neural tube. Despite numerous cell and animal studies, molecular details on CELSR proteins are sparsely available, precluding an integrative understanding of CELSR biology. Here, we report the 3.8 Å cryo-EM reconstruction of the CELSR1 ECR which enables unambiguous assignment of the 14 domains within the structure. These domains form a compact module mediated by robust and evolutionarily conserved interdomain interactions. This compact module provides a plethora of potential ligand binding sites for the various adhesion domains within the structure and hints at a model where the compact module could be pulled apart by robust mechanical force. We present biophysical evidence that the CELSR1 ECR forms an extended dimer in the presence of Ca2+, which we propose represents the cadherin repeats dimerizing in a configuration similar to protocadherins. We employ cellular assays with full-length CELSR1 and truncation constructs to assess the adhesive and signaling functions of this protein. We assign the N-terminal CADH1-8 module as necessary for cell adhesion and we show the C-terminal CAHD9-GAIN module regulates signaling. Our work provides molecular context to the literature on CELSR function and lays the groundwork for further elucidation of structure/function relationships." Authors & Affiliations "Garbett, Krassimira, Kordon, Szymon P., Shearer, Tanner, Sando, Richard C.*, and Araç, Demet* Department of Biochemistry and Molecular Biology, The University of Chicago Neuroscience Institute, Institute for Biophysical Dynamics, and the Center for Mechanical Excitability, The University of Chicago, Chicago, IL, 60637, USA. Department of Pharmacology, Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN 37240, USA." About Sumit Bandekar "I am an NIH F32 postdoctoral fellow in the Araç Laboratory at the University of Chicago. I study adhesion GPCRs using structural biology perspective and I am interested in how the large multidomain extracellular region regulates receptor function. In my free time, I enjoy biking around Chicago and trying new breweries and restaurants." Sumit Bandekar on the web Araç Laboratory at UChicago X (Twitter) LinkedIn Unveiling the GPS Cleavage Mechanism in ADGRL1 with QM/MM Florian Seufert Abstract "Adhesion G-protein coupled receptors (aGPCR) are a family of 32 mammalian proteins with a defining conserved GPCR autoproteolysis inducing (GAIN) domain that catalyzes receptor self-cleavage at a GPCR proteolysis site (GPS). The autoproteolytic mechanism has been previously proposed, but remains to be validated.⁠ A previous computational study has uncovered variable flexible protein regions, whose dynamics mediate solvent-accessibility of the catalytically active GPS triad HL|S/T, however classical molecular dynamics approaches fall short of explaining the chemical reaction.⁠ Using a multiscale QM/MM approach - combining computational quantum mechanics with classical molecular dynamics - to study the GAIN domain cleavage mechanism of ADGRL1 reveals the sequence of events at the electronic level, suggesting relative energies for the individual states during the reaction, and provides insight into the structural determinants for a successful GPS cleavage exceeding the catalytically active GPS triad. By directly scanning and comparing energetic sequences of reaction steps, the most likely pathway and the individual contribution of surrounding protein residues can be elucidated. A stable π-edge contact with a conserved phenylalanine and a protonated glutamate side-chain catalyze the reactant conformation. MD simulations with the parameterized ester intermediate reveal a protonation-dependent dynamic desolvation of the GPS for subsequent ester hydrolysis by restricting water conformations. Mutational experiments on residues of interest showed that restoring the Phe-His interaction in the uncleaving ADGRB3 GAIN domain partially re-instates cleavage, while its deletion reduces cleavage in the ADGRL1 GAIN domain.⁠ We present a two-step GPS cleavage model and respective determinants of the reaction." Authors & Affiliations "Chung, Yin Kwan2, Pohl, Fabian2, Batebi, Hossein1 Sträter, Norbert3 , Langenhan, Tobias2 & Hildebrand, Peter Werner1 1 Institute of Medical Physics and Biophysics, Medical Faculty, Leipzig University, Germany 2 Rudolf Schönheimer Institute of Biochemistry, Division of General Biochemistry, Medical Faculty, Leipzig University, Germany 3 Institute of Bioanalytical Chemistry, Leipzig University, Germany" About Florian Seufert "Florian Seufert has studied Biochemistry in Leipzig, before joining the Hildebrand Lab in Leipzig for his PhD." Florian Seufert on the web LinkedIn ResearchGate < Previous Session Next Session >

Home → Flash News → A new study from the Hudson Lab at the University of Glasgow shows that the FFA receptor antagonist AH7614 is actually an inverse agonist - suppressing fat cell formation, boosting lipolysis and reducing glucose uptake. Explore how targeting FFA4 could help fight metabolic disorders. Catch up with the latest research conducted in the Hudson lab in Ep. 161 of the Dr. GPCR Podcast. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://www.ecosystem.drgpcr.com/gpcrs-in-cardiology-endocrinology-and-taste/inverse-agonism-of-the-ffa4-free-fatty-acid-receptor-controls-both-adipogenesis-and-mature-adipocyte-function #GPCR #drGPCR #FFA4 #metabolism #adipocytes” Published on April 7, 2025 Category GPCR Weekly News A new study from the Hudson Lab at the University of Glasgow shows that the FFA receptor antagonist AH7614 is actually an inverse agonist - suppressing fat cell formation, boosting lipolysis and reducing glucose uptake. Explore how targeting FFA4 could help fight metabolic disorders. Catch up with the latest research conducted in the Hudson lab in Ep. 161 of the Dr. GPCR Podcast. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https:// www.ecosystem.drgpcr.com/gpcrs-in-cardiology-endocrinology-and-taste/inverse-agonism-of-the-ffa4-free-fatty-acid-receptor-controls-both-adipogenesis-and-mature-adipocyte-function #GPCR #drGPCR #FFA4 #metabolism #adipocytes Previous Next Recent Articles

Home → Flash News → Unlock the full potential of the Dr. GPCR platform by updating your profile 🧬 Find like-minded scientists, and colleagues who work on the same topic as you 🙌 ✳️Go to https://www.ecosystem.drgpcr.com/account/my-account and update your profile #gpcr #drgpcr Published on January 22, 2025 Category Dr. GPCR Profiles Unlock the full potential of the Dr. GPCR platform by updating your profile 🧬 Find like-minded scientists, and colleagues who work on the same topic as you 🙌 ✳️Go to https://www.ecosystem.drgpcr.com/account/my-account and update your profile #gpcr #drgpcr Previous Next Recent Articles

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Scott Struthers R. Scott Struthers, Ph.D., is our co-founder and has served as our President and Chief Executive Officer since December 2008. Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc., from 1998 to 2008. At Neurocrine, he initiated and led the effort to discover and develop orally active, nonpeptide GnRH antagonists, including elagolix. Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets. Between 1992 to 1995 he led contract research efforts at Biosym Technologies to develop and apply computational tools for drug discovery. In 2021, Dr. Struthers co-founded and serves as board chair at Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for oncology indications. In addition, he is a member of the board of directors of the San Diego Entrepreneurs Exchange, a nonprofit organization that provides resources for early-stage start-ups, which he co-founded in [2009.] R. Scott Struthers on the web LinkedIn Google Scholar Crinetics Radionetics Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Brendan Wilkins About Brendan Wilkins "Brendan completed his undergraduate training at the University of New South Wales (UNSW) Sydney, Australia in 2016 with first class Honours in Pharmacology. In his Honours year, Brendan explored small molecule allosteric modulators of the β2-adrenoceptor under the tutelage of Dr Angela Finch. Since then, Brendan worked as a research assistant at the Victor Chang Cardiac Research Institute where he investigated the orphan G protein-coupled receptor (GPCR), GPR37L1. Brendan is now a final year PhD candidate in the Orphan Receptor Laboratory headed by Associate Professor Nicola J Smith at UNSW Sydney, Australia. Brendan’s PhD project focuses on the orphan GPCR GPR146. This project aims to characterise the molecular pharmacology of GPR146 and to validate the proposed ligands of GPR146 in line with IUPHAR-NC guidelines on deorphanisation of orphan GPCRs. Brendan is currently looking for post-doctoral positions to begin in mid-2024" Brendan Wilkins on the web UNSW Sydney Google Scholar ResearchGate LinkedIn Twitter Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Debbie Hay About this episode Dr. Debbie Hay is presently a professor at the Department of Pharmacology and Toxicology at the University of Otago after spending 18 years at the University of Auckland. Her work is primarily focused on class B GPCRs and their interactions with RAMPs. Debbie obtained a Ph.D. in Molecular Pharmacology from Imperial College London in the UK. She has gained experience from working in academia and at GSK as an industrial trainee. Join me and learn more about Debbie’s career and what she learned through her experiences as a scientist. Dr. Debbie Hay on the web LinkedIn Wikipedia University of Otago University of Auckland Google Scholar Pubmed Research Gate Twitter Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Terry Hébert About this episode Dr. Terry Hébert is a Professor within the Department of Pharmacology & Therapeutics at McGill University. Much of his work is based on GPCR signaling in the context to cardiovascular diseases. In this special episode of the Dr.GPCR podcast , we re-connected with Dr. Terry Hebert to chat about how he and his team has been adapting to the new reality of working remotely. Terry tells us about the importance of adapting, communicating, and being mindful of those around us. Dr. Terry Hébert on the web Terry Hébert | Institute of Health Sciences Education Hébert Lab LinkedIn Hébert Lab The GPCR Consortium PubMed Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dylan Eiger About Dylan Eiger Dylan Eiger is currently an MD/Ph.D. student at Duke University School of Medicine. He received his B.S. in Chemistry from Duke University in 2016 where he worked in the lab of Dr. Stephen Craig and studied polymer chemistry and material science. He is currently finishing his Ph.D. in the lab of Dr. Sudarshan Rajagopal, a former postdoctoral fellow of Dr. Robert J. Lefkowitz . Dylan's graduate research focuses on the mechanisms underlying biased signaling at GPCRs, specifically, the role of differential receptor phosphorylation (phosphorylation barcodes) and subcellular GPCR signaling in directing functionally selective responses. He primarily studies the chemokine receptor CXCR3 as it has three naturally occurring ligands and thus serves as an endogenous example of biased agonism. After finishing his MD/Ph.D., Dylan plans to complete his residency training in Internal Medicine and subsequently pursue fellowship training in Cardiology. He hopes to continue his research on biased agonism at GPCRs with a particular focus on the treatment of cardiovascular disease. Dylan Eiger on the web LinkedIn Twitter PubMed Website Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Robert F. Bruns About Dr. Robert F. Bruns Fred Bruns discovered the first positive allosteric modulator (PAM) of a GPCR in the late 1980s while working at Warner-Lambert/Parke-Davis. The work was published in 1990. After 7 years at WL/PD and 26 years at Eli Lilly & Co., he retired at the end of 2014 and since then has been writing papers on his final major project at Lilly, a dopamine D1 PAM series that has advanced through Phase 2 clinical trials. Fred obtained an A.B. in Psychology from Washington University in St. Louis, followed by a Ph.D. in Neurosciences at the University of California, San Diego. His doctoral dissertation was the first large-scale study of structure-activity relationships for adenosine receptors. During a joint postdoc with John W Daly at NIH and Solomon Snyder at Johns Hopkins, he developed the first adenosine receptor binding assay. He then joined WL/PD, where his lab demonstrated the existence of two subtypes of the adenosine A2 receptor, A2a and A2b. In 1988, he joined Lilly as a receptor biologist in charge of a high-throughput screening lab. He taught himself chemoinformatics as a way to optimize compound selection for screening, and in 1997 switched to computational chemistry full-time. He supported the D1 PAM project in various roles from its inception in 2002 until selection of a clinical candidate in 2013. Dr. Bruns has over 80 publications and 11,000 citations, with an h-index of 47. Dr. Robert F. Bruns on the web ResearchGate LinkedIn Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Caron Tribute Part 3 About Marc Caron Dr. Caron and his family moved to Durham, NC in 1977, following receipt of his BSc in Chemistry from Laval University and his Ph.D. from the University of Miami. He joined the faculty of Laval University School of Medicine in 1975 and then returned to join Duke’s faculty, where he remained as a James B. Duke Professor until his death. He and his laboratory members studied the mechanisms of action and regulation of hormones and neurotransmitters and how they might underlie brain and behavior disorders such as schizophrenia, Parkinson's disease, attention-deficit hyperactivity disorder, mood disorders, and addiction. Among his many honors, Dr. Caron was an investigator of the Howard Hughes Medical Institute from 1992 to 2004, a member of the American Academy of Arts & Sciences, a fellow of the American Association for the Advancement of Science, and a recipient of the Julius Axelrod Award. An authoritative and prolific scientist, with over 650 scientific publications, he is most beloved as a mentor and his relentless encouragement that shaped the careers of hundreds of scientists worldwide. About our panelists in alphabetical order and the year they first met Dr. Caron Dr. Jean Martin Beaulieu (2003) Dr. Laura Bohn (1999) Dr. Kathleen Caron - Co-host- (1970) Dr. Henrik Dohlman (1987) Dr. Kafui Dzirasa (2006) Dr. Yasushi Masuda (2004) Dr. Marco Pardo (2002) Dr. Vania Prado (2002) Dr. Amy Ramsey (2008) Dr. Bryan Roth (current) Dr. Ali Salahpour (2007) Dr. Lauren Sloksy (2020) Dr. Josh C Snyder (2012) Dr. William Wetsel (current) Memories our panelists shared with us Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Sri Kosuri About Dr. Sri Kosuri Sri is a biologist that has helped build technologies, labs, and companies in synthetic biology, functional genomics, and bioinformatics over the last 20 years. He is passionate about developing more rational ways to understand and engineer biology. Sri is a co-founder at Octant and an Associate Professor at UCLA in the Chemistry and Biochemistry Department. His lab has worked on building large-scale ways of empirically exploring questions in protein biochemistry, human genetic variation, gene regulation, chemical biology, synthetic biology, and functional genomics. Sri previously worked at the Wyss Institute and Harvard, where he built numerous technologies in gene synthesis, DNA information storage, gene editing, and large-scale multiplexed assays. He helped build Gen9, a gene synthesis company, as a member of the SAB and was the first employee of Joule Unlimited, an engineered algal biofuel company. He is a Searle Scholar (2015), NIH New Innovator (2014), and received his ScD in Biological Engineering at MIT and BS in Bioengineering at UC Berkeley. Sri is originally from New Jersey, Philadelphia, and Kansas and was born in North Carolina. He enjoys eating, getting outdoors, and traveling with his wife and two children. Dr. Sri Kosuri on the web Octant Kosuri Lab Twitter LinkedIn Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>